Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia.  PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia.  FB6001 is expected to be administered subcutaneously every 3-6 months.  AFFiRiS’ phase 1 clinical data has shown FB6001 is safe and tolerable with potent cholesterol-lowing effect.  Frontier Biotech plans to start clinical development in China soon.